Business Model and Strategy (ESG)
Brief description of the business model and strategic areas.
The activity of SYNERGA.fund S.A. focuses on the implementation of an innovative medical project in the field of biotechnology and advanced cell therapies.
ONGENO Operational Structure
Capital, scientific, and operational cooperation for the implementation of an innovative therapy for multiple sclerosis (MS).
JRH ASI S.A.
Capital PartnerProvides investment and strategic support as well as ownership supervision over the proper course and financing of the project.
Ongeno sp. z o.o.
Intellectual PropertyContributes industrial property rights and proprietary copyrights to the therapies and technologies used in the medical experiment.
Dr n. med. W. Orłowski
Scientific & Medical PartnerResponsible for the research and scientific part, development of medical procedures, and supervision of transplants in MS patients.
SYNERGA.fund S.A.
Commercialization & ScalingResponsible for global marketing of the therapy, building awareness of the ONGENO brand, and scaling operations to international markets.
ONGENO Therapy in the Treatment of Multiple Sclerosis (MS)
The project focuses on the clinical and commercial implementation of an advanced treatment method for multiple sclerosis using autologous bone marrow stem cell transfer. Implementation is based on integrating intellectual property rights with the clinical and medical expertise of the partners.
Sustainable Development Strategy (ESG) Information
At this moment, no formalized sustainable development strategy (ESG) has been implemented. These issues will be taken into account at the stage of developing new directions of development.